We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Telomere Length Abnormalities Linked to Lymphoma Development

By LabMedica International staff writers
Posted on 11 May 2026

Lymphoma comprises a diverse group of malignancies that arise from lymphocytes and affect about 1 million people in the United States. Early detection and long-term monitoring remain difficult, particularly for families with inherited cancer risk. Researchers are working to better understand how aging immune cells contribute to cancer development. New findings suggest that unusually long telomeres—the protective caps at the ends of chromosomes—linked to inherited genetic changes may increase lymphoma risk and offer insight into how the disease develops.

Researchers at the Johns Hopkins Kimmel Cancer Center and the Telomere Clinic at Johns Hopkins identified a genetic syndrome in which inherited loss-of-function variants in the POT1 gene maintain unusually long telomeres in immune cells. POT1 normally constrains telomere length, but when one gene copy is inactivated, telomeres become excessively long. In lymphocytes, this blunts the expected age-related telomere attrition and can enable survival of clones that accumulate cancer-associated mutations.


Image: While long telomeres are often viewed as protective against aging, a new study shows that extended cellular longevity may increase blood cancer risk (image credit: Adobe Stock)
Image: While long telomeres are often viewed as protective against aging, a new study shows that extended cellular longevity may increase blood cancer risk (image credit: Adobe Stock)

In an analysis of cancer histories and biospecimens from 51 individuals across 24 families carrying POT1 variants, hematologic malignancies and thyroid cancer were the most common diagnoses after melanoma. Three-quarters of the blood cancers arose from lymphocytes. Rarer, slow-growing myeloid neoplasms were also observed, sometimes occurring alongside lymphoma in the same individual.

To test generalizability, the team evaluated 210 adults with POT1 variants in the UK Biobank, identifying an eightfold higher risk of lymphoma, with 45% developing a lymphoid cancer by age 80. Among carriers without a lymphoma diagnosis, early lymphocyte clonality was detectable; after age 60, nearly all had expanded lymphocyte clones, and most harbored mutations commonly associated with lymphoma. Sixty percent exhibited ultra-long telomeres within the top 1% of the population, while others showed shorter lengths consistent with clonal expansion.

Telomerase activity is typically tightly controlled, but in lymphocytes lacking normal POT1 function, regulation appears disrupted, providing opportunities for further elongation as immune cells divide. The study, published in Blood, suggests a mechanism by which extended cellular longevity confers lymphoma susceptibility and may explain why some individuals develop multiple malignancies, including melanoma. 

The authors also note that telomere shortening with aging may serve a protective role by pruning damaged cells. With no established screening protocols for lymphoma, optimal surveillance for POT1 carriers remains uncertain and ranges from careful clinical monitoring to more proactive approaches pending further research.

“Our findings point to a new mechanism of lymphoma susceptibility that is linked to extended cellular longevity,” said Mary Armanios, M.D., professor of oncology and genetic medicine and director of the Telomere Clinic at Johns Hopkins. “In this setting, lymphocytes retain a kind of youthfulness that allows cancer-associated mutations to persist and expand over time.”

“Our data suggest that, for now, telomere length clinical testing should be reserved for individuals with variants in the gene that have unclear significance,” said Armanios.

Related Links
Johns Hopkins Kimmel Cancer Center
Telomere Clinic at Johns Hopkins


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
Automated Urinalysis Solution
UN-9000
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]

Latest BioResearch News

Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
11 May 2026  |   BioResearch

Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
11 May 2026  |   BioResearch

Study Links Abnormal Gene Splicing to Treatment Response in Metastatic Kidney Cancer
11 May 2026  |   BioResearch



ADLM